Your Arthritis Numbers Improved. Why Hasn’t Life Caught Up?

Imagine sitting across from your rheumatologist and hearing some genuinely good news. The swelling is down. The examination is reassuring. Your rheumatoid arthritis is in remission, or at least showing low disease activity.

That should matter. It does matter. Rheumatoid arthritis can damage joints and affect organs beyond them, and controlling the disease is a serious achievement.

But suppose you leave the appointment and still cannot comfortably make dinner, manage a full workday, or carry your grandchild. You are grateful for the medical progress, yet the life you expected to reclaim has not quite returned.

Now you have an uncomfortable question: If the numbers are better, why doesn’t everyday life feel better in the same proportion?

Today, October 12, is World Arthritis Day. The European Alliance of Associations for Rheumatology has chosen “Achieve Your Dreams” as its 2026 campaign theme. The Global Remission Coalition is asking us to consider why remission should be understood in relation to quality of life, not just a number.

A peer-reviewed study published September 14, 2026, makes that conversation more concrete. It examined what happens when measures of rheumatoid arthritis disease activity are compared with the way people report their health and function. The findings are nuanced, which is exactly why they are worth reading.

A Better Score Is Real Progress. It Is Not the Whole Outcome.

Rheumatoid arthritis is an autoimmune disease in which the immune system attacks tissues, particularly the lining of joints. It can cause swelling, pain, stiffness, fatigue, and progressive damage. The National Institute of Arthritis and Musculoskeletal and Skin Diseases also notes that it can affect the lungs, heart, eyes, and other tissues.

For this reason, rheumatologists do not evaluate success by asking whether a patient had a good Tuesday. They monitor signs of disease activity and use treatments intended to control inflammation and prevent damage. Disease-modifying antirheumatic drugs are central to this work. Symptom relief matters, but it is not the only objective.

Clinical remission therefore has a particular meaning. It is not a promise that every joint will feel young again, every hour will be energetic, or every previous physical limitation will disappear.

The American College of Rheumatology and EULAR remission criteria incorporate clinical measures such as tender and swollen joint counts, inflammatory markers in some definitions, and the patient’s own assessment. These criteria have been tested for their ability to predict important outcomes, including physical function and protection against radiographic progression.

That is not bureaucracy. It is a necessary part of treating a disease that can continue causing harm even when a person becomes accustomed to its symptoms.

But a validated measure can still have a boundary. It can tell us something essential without telling us everything.

What the September 2026 Study Actually Found

Researchers led by Joan M. Nolla examined 275 adults with rheumatoid arthritis, all older than 50, and 300 comparison participants with a similar age and sex distribution. They compared measures of fatigue and health-related quality of life while classifying rheumatoid arthritis using two different tools.

One, called DAS28, incorporates joint assessment and other measures of disease activity. The other, RAPID3, is based on patient-reported physical function, pain, and overall assessment. They are not interchangeable instruments, and the study did not assume they should produce identical answers.

Among patients classified as being in remission by DAS28, physical quality-of-life scores were statistically lower than those of controls. Yet fatigue scores and mental quality-of-life scores in that same remission group were not statistically different from controls. That distinction is crucial. The study does not establish that people in remission are necessarily more fatigued than everyone else.

Among patients classified as having low disease activity by DAS28, mental quality-of-life scores were lower than controls after adjustment for multiple comparisons. Some other differences, including fatigue, did not remain statistically significant after that adjustment.

There was another revealing result: agreement between DAS28 and RAPID3 disease-activity categories was limited, with a weighted kappa of 0.35. When the tools disagreed, RAPID3 more often placed patients in a higher activity category.

The lesson is not that one instrument is fraudulent. The lesson is that different instruments capture different aspects of the same person’s experience. The researchers concluded that inflammatory disease activity and patient-reported health should be assessed as complementary information. Read the original study.

The Difference Between Disease Control and Lived Capacity

Consider two people who both meet a clinical target for rheumatoid arthritis.

One can walk several miles, work comfortably, sleep well, and participate in the activities she values. The other has persistent pain, reduced strength, poor sleep, and difficulty getting through an ordinary afternoon. Their disease-activity category may be similar while their functional lives are not.

That difference does not automatically mean the second person has uncontrolled rheumatoid arthritis. It also does not mean her experience is exaggerated or that she needs to think more positively.

Residual limitations may have several contributors: previous joint damage, muscle weakness, another pain condition, sleep disruption, medication effects, anemia, depression, or something unrelated to rheumatoid arthritis. Active inflammatory disease can also be missed or change over time, which is why new or worsening symptoms still need clinical reassessment.

The purpose of a whole-person investigation is not to pick whichever explanation sounds most holistic. It is to ask which explanation is supported by the person’s history, examination, appropriate tests, and lived experience.

A rheumatologist may be measuring whether the disease is controlled. The person is also asking whether she can return to her work, relationships, responsibilities, and interests. Those are different questions, and both deserve attention.

Your Goals Are Not a Soft Endpoint

There is something I appreciate about the 2026 World Arthritis Day theme: “Achieve Your Dreams.” It refuses to reduce a person to the condition she is managing.

Of course, not every ambition is possible on the timetable we prefer. Severe illness can impose genuine limitations. Pretending otherwise is neither compassionate nor useful.

But what a person wants to do is still meaningful clinical information. A pianist wants to use her hands. A parent wants to lift a child. A business owner wants enough stamina to lead a meeting without paying for it the following day. A traveler wants to navigate an airport. Someone else wants to garden without losing the rest of the weekend to pain.

Those are not vague lifestyle wishes. They describe function, endurance, recovery, participation, and independence. They can help a care team understand which limitations matter most and whether additional rehabilitation, symptom evaluation, accommodations, or treatment adjustments should be considered.

A treatment target tells us what medicine is trying to control. A lived goal tells us what the person is trying to reclaim.

Neither should erase the other.

The Body Does Not Separate Its Experience Into Clinic Departments

Rheumatoid arthritis is a specific autoimmune condition, and it should be treated as one. Whole-person thinking does not turn it into a metaphor for stress, a mineral deficiency, or unresolved emotion.

At the same time, a person with rheumatoid arthritis does not stop having a nervous system, muscles, sleep cycles, family relationships, professional responsibilities, or a physical environment.

Pain can change sleep. Poor sleep can influence pain experience and daytime function. Reduced movement can affect strength and confidence. Work demands can make recovery time harder to protect. Anxiety about a flare can change plans long before a flare arrives. Support at home can determine whether a treatment plan is practical.

These dimensions are not separate boxes that we ceremonially reconnect with the word holistic. They are already operating together. The important work is identifying which interactions matter for this person without claiming that any one of them caused her autoimmune disease.

That is also why a single symptom should not automatically become a single explanation. In an earlier TEI article, “Fatigue Is a Symptom. It Is Not an Explanation,” I explored the difference between experiencing exhaustion and knowing what produces it. The same discipline applies here: persistent limitation is a reason to investigate, not permission to invent a cause.

A Better Appointment Begins With a Better Question

If you are managing rheumatoid arthritis, try bringing one concrete goal to your next clinical appointment, along with a short description of what is interfering with it.

Rather than reporting only that you are tired, explain that you can manage a morning meeting but cannot reliably complete an afternoon of work. Rather than saying your hands hurt, explain that fastening buttons or opening containers has become difficult. Notice whether symptoms vary with sleep, activity, medication timing, or the presence of swelling and stiffness.

Then ask two related questions: How well controlled is my rheumatoid arthritis? And what else might be limiting my function?

Depending on the answer, the next step might be a disease-activity reassessment, medication review, occupational or physical therapy, evaluation of sleep or another condition, or an individualized activity plan. A qualified clinician should guide those decisions. Do not stop or change prescribed disease-modifying medication because a score improved or because an article suggests that quality of life matters.

If you have persistent swollen joints, new symptoms, worsening function, or unexplained systemic symptoms, seek appropriate medical evaluation rather than waiting for a routine visit. Rheumatoid arthritis can affect more than the joints, and prompt attention to concerning changes matters. NIAMS guidance.

The Number Should Serve the Person

I am not interested in replacing medical evidence with personal preference. We need both. A person can feel reasonably well while disease activity remains concerning, just as she can meet a clinical target while daily life remains difficult.

The point is to stop asking one kind of measurement to answer every kind of question.

A disease-activity score helps a clinician understand and manage rheumatoid arthritis. A conversation about what you can do, what you cannot do, and what matters to you helps reveal the consequences of living with it.

World Arthritis Day is an appropriate moment to recognize that distinction. Progress should be measurable, but it should also be meaningful.

A better number is a medical achievement. A better life is the human reason we wanted progress in the first place.

References & Documents Cited

Nolla JM, Valencia-Muntalà L, Benavent D, et al. Beyond Disease Activity: Fatigue and Health-Related Quality of Life in Rheumatoid Arthritis Remission and Low Disease Activity. Journal of Clinical Medicine. 2026;15(18):7133. Published September 14, 2026. DOI: 10.3390/jcm15187133. PubMed record.

Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis & Rheumatology. 2023;75(1):15–22. First published October 23, 2022. DOI: 10.1002/art.42347.

European Alliance of Associations for Rheumatology (EULAR). World Arthritis Day 2026: Achieve Your Dreams. Official 2026 campaign page. EULAR.

Global Remission Coalition. World Arthritis Day 2026: Remission is More Than a Number. Official 2026 campaign page. World Arthritis Day.

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Rheumatoid Arthritis and Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take. Overview · Clinical care.

Bala V, Hafström I, Svensson B, Ajeganova S. Persistently different patterns of patient’s global assessment of health in rheumatoid arthritis are associated with pain and impaired function more than with inflammation: an inception cohort study over 15 years. RMD Open. 2025. DOI: 10.1136/rmdopen-2024-004744.

FAQs

Can you still have symptoms when rheumatoid arthritis is in remission?
Yes. Some people experience pain or functional limitations even when inflammatory disease activity is low; those symptoms need evaluation rather than an assumption that inflammation is either present or absent.

Does rheumatoid arthritis remission mean fatigue always continues?
No. In the 2026 study, fatigue scores for patients in DAS28 remission were not statistically different from controls. Fatigue may occur, but it is not universal or automatically attributable to active rheumatoid arthritis.

What is the difference between DAS28 and RAPID3?
DAS28 is a composite disease-activity measure incorporating joint assessment and other clinical information; RAPID3 emphasizes patient-reported function, pain, and overall assessment. They measure overlapping but different aspects of health.

Should I stop medication when rheumatoid arthritis is in remission?
No medication change should be made without the treating clinician. Disease-modifying therapies are used to control rheumatoid arthritis and help prevent damage; treatment decisions require individual assessment.

How can I explain persistent limitations to my rheumatologist?
Describe a specific activity that is difficult, when symptoms occur, and whether there is swelling, pain, stiffness, fatigue, or sleep disruption. This adds functional context to disease-activity assessment.